INFRAFRONTIER / IMPC Stakeholder Meeting 2018


Published 16th August 2018

Advancing Rare Disease Research and Gene Therapy Applications with Animal Models

The second Stakeholder Meeting of INFRAFRONTIER, the European Research Infrastructure for phenotyping and archiving of model mammalian genomes, will be jointly organized with the International Mouse Phenotyping Consortium. Thematic focus of the meeting is on advancing Rare Disease research and gene therapy applications with animal models.

The Stakeholder Meeting provides an excellent opportunity to support a better alignment of INFRAFRONTIER / IMPC platforms with current Rare Disease research and personalised medicine initiatives, and supports interactions with human genetics centers and clinical consortia. New partnerships can support the rapid impact of mouse functional genomics analyses on the understanding of human genetic variation and disease, and the translation into diagnostic and therapeutic approaches.

The Stakeholder Meeting will be structured into three main parts:

  • Advancing Rare Disease research with animal models
  • Gene therapy applications using animal models
  • Young Investigator / Stakeholder presentations

Meeting aims are to:

  • Raise awareness of INFRAFRONTIER / IMPC platforms among the Rare Disease community
  • Present use cases for the utility of animal models to advance Rare Disease research
  • Share advances in gene therapy applications, including gene-editing approaches to cure human diseases
  • Strengthen interactions with Rare Disease and clinical research consortia
  • Support presentation of use cases by Young Investigators

Confirmed speakers include:

  • Fatima Bosch, UAB,  ES
  • Steve Brown, MRC Harwell,  UK
  • Jacob Corn, ETH Zurich,  CH
  • Colin Fletcher, NIH,  USA
  • Pietro Genovese, SR-TIGET,  IT
  • Melissa Haendel, Oregon Health & Science University,  USA
  • Yann Herault, PHENOMIN-ICS,  FR
  • Martin Hrabě de Angelis, Helmholtz Zentrum München & INFRAFRONTIER GmbH,  GE
  • Fabio Mammano, CNR-IBCN,  IT
  • Federico Mingozzi, Spark Therapeutics,  IT
  • Lluis Montoliu, CSIC-CNB,  ES
  • Anna Need, GenomicsEngland,  UK
  • Helene Puccio, IGBMC,  FR
  • Olaf Riess, University of Tübingen,  GE
  • Wolfgang Wurst, Helmholtz Zentrum München,  GE


For more information please visit the INFRAFRONTIER website: INFRAFRONTIER / IMPC Stakeholder Meeting 2018

For updates on the meeting please follow INFRAFRONTIER on Twitter:


Published 16th August 2018